Activation of necroptosis pathway in podocyte contributes to the pathogenesis of focal segmental glomerular sclerosis. 2022

Haoqiang Hu, and Mengyuan Li, and Binfeng Chen, and Chaohuan Guo, and Niansheng Yang
Department of Nephrology, Affiliated Dongguan People's Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, 523000, China.

BACKGROUND Focal segmental glomerulosclerosis (FSGS) is characterized by podocyte damage and severe proteinuria. The exact mechanism of podocyte damage and loss remains unclear. Necroptosis, a lytic form of programmed cell death mediated by RIP3 and MLKL, has emerged as an important cell death pattern in multiple tissues and cell types. Necroptosis in FSGS has not been investigated. METHODS Public GEO data regarding podocyte treated with vehicle or adriamycin (ADR) was identified and analyzed. Cultured human podocytes were used to explore the activation of necroptosis upon ADR stimulation. The expression of necroptosis pathway molecules, p-RIP3 and p-MLKL, was examined in the glomeruli and defoliated urinary podocytes of patients with FSGS. The effect of necroptosis inhibition was assessed in ADR-induced glomerulopathy mice using GSK872. RESULTS Publicly available RNA-sequencing data analysis showed that both necroptosis and NLRP3 inflammasome pathway were up-regulated in ADR-injured podocyte. Immunofluorescent staining showed increased expression of p-RIP3 and p-MLKL, the active forms of RIP3 and MLKL, in podocytes of FSGS patients and ADR-induced glomerulopathy mice but not in the normal control. GSK872, an RIP3 kinase inhibitor, significantly inhibited the expression of p-RIP3, p-MLKL and activation of NLRP3 in cultured podocytes treated with ADR. GSK872 treatment of mice with ADR-induced nephropathy resulted in the reduced expression of p-RIP3, p-MLKL, NLRP3 and caspase-1 p20. GSK872 also significantly inhibited the expression of p-MLKL in the podocytes of ADR-induced nephropathy, resulting in the attenuation of proteinuria and renal histological lesions. CONCLUSIONS Necroptosis pathway might be a valuable target for the treatment of FSGS.

UI MeSH Term Description Entries
D007674 Kidney Diseases Pathological processes of the KIDNEY or its component tissues. Disease, Kidney,Diseases, Kidney,Kidney Disease
D011507 Proteinuria The presence of proteins in the urine, an indicator of KIDNEY DISEASES. Proteinurias
D004317 Doxorubicin Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN. Adriamycin,Adriablastin,Adriablastine,Adriblastin,Adriblastina,Adriblastine,Adrimedac,DOXO-cell,Doxolem,Doxorubicin Hexal,Doxorubicin Hydrochloride,Doxorubicin NC,Doxorubicina Ferrer Farm,Doxorubicina Funk,Doxorubicina Tedec,Doxorubicine Baxter,Doxotec,Farmiblastina,Myocet,Onkodox,Ribodoxo,Rubex,Urokit Doxo-cell,DOXO cell,Hydrochloride, Doxorubicin,Urokit Doxo cell
D005923 Glomerulosclerosis, Focal Segmental A clinicopathological syndrome or diagnostic term for a type of glomerular injury that has multiple causes, primary or secondary. Clinical features include PROTEINURIA, reduced GLOMERULAR FILTRATION RATE, and EDEMA. Kidney biopsy initially indicates focal segmental glomerular consolidation (hyalinosis) or scarring which can progress to globally sclerotic glomeruli leading to eventual KIDNEY FAILURE. Glomerulonephritis, Focal Sclerosing,Hyalinosis, Segmental Glomerular,Focal Segmental Glomerulosclerosis,Glomerulosclerosis, Focal,Hyalinosis, Segmental,Segmental Glomerular Hyalinosis,Focal Glomerulosclerosis,Focal Sclerosing Glomerulonephritides,Focal Sclerosing Glomerulonephritis,Glomerular Hyalinosis, Segmental,Glomerulonephritides, Focal Sclerosing,Sclerosing Glomerulonephritides, Focal,Sclerosing Glomerulonephritis, Focal,Segmental Glomerulosclerosis, Focal,Segmental Hyalinosis
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000071199 NLR Family, Pyrin Domain-Containing 3 Protein An NLR protein that contains an N-terminal PYRIN DOMAIN and ATP-binding site and 9 C-terminal LEUCINE-rich repeats; it is expressed primarily by MACROPHAGES. It is a core component of the INFLAMMASOME and directs its assembly in response to pathogen infection and damage-associated stimuli. Mutations in the NLRP3 gene are associated with FAMILIAL COLD AUTOINFLAMMATORY SYNDROME. Cold Autoinflammatory Syndrome 1 Protein,NACHT, LRR and PYD Domains-Containing Protein 3,NLRP3 Protein,NACHT, LRR and PYD Domains Containing Protein 3,NLR Family, Pyrin Domain Containing 3 Protein
D000079302 Necroptosis A form of regulated cell death initiated by perturbations of extracellular or intracellular homeostasis that trigger a specific cell death pathway involving the activation of RIPK3 and MLKL (mixed lineage kinase domain like pseudokinase). Morphological changes include cytoplasmic and organellar swelling, rupture of the PLASMA MEMBRANE, and CHROMATIN CONDENSATION.
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012313 RNA A polynucleotide consisting essentially of chains with a repeating backbone of phosphate and ribose units to which nitrogenous bases are attached. RNA is unique among biological macromolecules in that it can encode genetic information, serve as an abundant structural component of cells, and also possesses catalytic activity. (Rieger et al., Glossary of Genetics: Classical and Molecular, 5th ed) RNA, Non-Polyadenylated,Ribonucleic Acid,Gene Products, RNA,Non-Polyadenylated RNA,Acid, Ribonucleic,Non Polyadenylated RNA,RNA Gene Products,RNA, Non Polyadenylated
D012598 Sclerosis A pathological process consisting of hardening or fibrosis of an anatomical structure, often a vessel or a nerve. Scleroses

Related Publications

Haoqiang Hu, and Mengyuan Li, and Binfeng Chen, and Chaohuan Guo, and Niansheng Yang
April 2014, The Journal of clinical investigation,
Haoqiang Hu, and Mengyuan Li, and Binfeng Chen, and Chaohuan Guo, and Niansheng Yang
May 1986, Archives of pathology & laboratory medicine,
Haoqiang Hu, and Mengyuan Li, and Binfeng Chen, and Chaohuan Guo, and Niansheng Yang
January 1996, Kidney international. Supplement,
Haoqiang Hu, and Mengyuan Li, and Binfeng Chen, and Chaohuan Guo, and Niansheng Yang
March 2012, Advances in chronic kidney disease,
Haoqiang Hu, and Mengyuan Li, and Binfeng Chen, and Chaohuan Guo, and Niansheng Yang
December 1985, Kidney international,
Haoqiang Hu, and Mengyuan Li, and Binfeng Chen, and Chaohuan Guo, and Niansheng Yang
December 1987, American journal of kidney diseases : the official journal of the National Kidney Foundation,
Haoqiang Hu, and Mengyuan Li, and Binfeng Chen, and Chaohuan Guo, and Niansheng Yang
October 2004, Nihon rinsho. Japanese journal of clinical medicine,
Haoqiang Hu, and Mengyuan Li, and Binfeng Chen, and Chaohuan Guo, and Niansheng Yang
November 2000, Renal failure,
Haoqiang Hu, and Mengyuan Li, and Binfeng Chen, and Chaohuan Guo, and Niansheng Yang
June 1980, The American journal of medicine,
Haoqiang Hu, and Mengyuan Li, and Binfeng Chen, and Chaohuan Guo, and Niansheng Yang
June 2022, Kidney international reports,
Copied contents to your clipboard!